HCAT vs. CDLX, VNET, EB, JG, HSTM, IAS, BMBL, GDS, HUYA, and TBLA
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Cardlytics (CDLX), VNET Group (VNET), Eventbrite (EB), Aurora Mobile (JG), HealthStream (HSTM), Integral Ad Science (IAS), Bumble (BMBL), GDS (GDS), HUYA (HUYA), and Taboola.com (TBLA). These companies are all part of the "computer programming, data processing, & other computer related" industry.
Health Catalyst (NASDAQ:HCAT) and Cardlytics (NASDAQ:CDLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
Health Catalyst has a net margin of -35.56% compared to Cardlytics' net margin of -55.23%. Health Catalyst's return on equity of -11.86% beat Cardlytics' return on equity.
In the previous week, Health Catalyst had 1 more articles in the media than Cardlytics. MarketBeat recorded 4 mentions for Health Catalyst and 3 mentions for Cardlytics. Health Catalyst's average media sentiment score of 0.94 beat Cardlytics' score of 0.43 indicating that Health Catalyst is being referred to more favorably in the media.
Health Catalyst has higher earnings, but lower revenue than Cardlytics. Health Catalyst is trading at a lower price-to-earnings ratio than Cardlytics, indicating that it is currently the more affordable of the two stocks.
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 68.1% of Cardlytics shares are owned by institutional investors. 2.7% of Health Catalyst shares are owned by company insiders. Comparatively, 4.4% of Cardlytics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Health Catalyst has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Health Catalyst presently has a consensus target price of $12.18, indicating a potential upside of 83.74%. Cardlytics has a consensus target price of $12.75, indicating a potential upside of 45.55%. Given Health Catalyst's higher probable upside, equities research analysts clearly believe Health Catalyst is more favorable than Cardlytics.
Cardlytics received 73 more outperform votes than Health Catalyst when rated by MarketBeat users. However, 67.74% of users gave Health Catalyst an outperform vote while only 58.20% of users gave Cardlytics an outperform vote.
Summary
Health Catalyst beats Cardlytics on 11 of the 18 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
